• Control Bionics partners with Tobii Dynavox, a global leader in Augmentative and Alternative Communication (AAC) solutions
• NeuroNode technology to be evaluated for a 6-month pilot in 5 U.S. states
• Collaboration aims to enhance access and use of communication technology for individuals with disabilities

Control Bionics Limited (ASX: CBL) has announced that it has entered into an agreement with Tobii Dynavox, a global leader in Augmentative and Alternative Communication (AAC) solutions, to evaluate a distribution partnership. Under the agreement, Tobii Dynavox will evaluate Control Bionics' NeuroNode technology for a six-month pilot period in five states in the northwestern region of the United States. The NeuroNode is designed to complement Tobii Dynavox's existing AAC solutions and provide eye gaze users with another way to access their technology. Tobii Dynavox is widely recognized as a global leader in the AAC market, with a long history of delivering innovative access and communication solutions to individuals with communication disabilities. Control Bionics, on the other hand, has been a pioneer in the use of surface electromyography (sEMG) for more than two decades, enabling individuals to control technology through minimal muscle activation where traditional access methods may not be viable. Control Bionics CEO, Jeremy Steele, expressed his excitement about the partnership, stating that it has the potential to meaningfully enhance how people access and use communication technology. While the initial pilot is for six months, the companies see real potential in the partnership and are looking to explore the opportunity for a broader U.S. expansion over time.